The immunogenic characteristics associated with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles

Biomaterials

Volumn 33, Issue 28, 2012, Pages 6843-6857

  Anish, Chakkumkal ^a   Goswami, Dinesh G ^a   Kanchan, Vibhu ^a   Mathew, Simi ^a   Panda, Amulya K ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Memory antibody titer; Multivalency; Particle phagocytosis; Polylactide particles; Vi polysaccharide antigens

Indexed keywords

ANTIBODY RESPONSE; ANTIBODY TITERS; CAPSULAR POLYSACCHARIDES; CARRIER PROTEINS; EXPERIMENTAL ANIMALS; MICRO-PARTICLES; MULTIVALENCY; POLY LACTIDE; POLYMER PARTICLES; POLYMERIC PARTICLES; POLYSACCHARIDE ANTIGEN; SALMONELLA TYPHI; SECONDARY ANTIBODIES; SINGLE-DOSE; TETANUS TOXOID;

ANIMALS; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; IMMUNIZATION; POLYSACCHARIDES; SALMONELLA;

ANTIBODIES;

IMMUNOGLOBULIN G; NANOPARTICLE; POLYLACTIDE; POLYMER; POLYSACCHARIDE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL ASSAY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DENSITY; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOGENICITY; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SALMONELLA TYPHI; SPLENOCYTES PROLIFERATION ASSAY; VACCINATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS; FEMALE; FLOW CYTOMETRY; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYSACCHARIDES, BACTERIAL; SURFACE PROPERTIES; TETANUS TOXOID; VACCINATION;

ANIMALIA; SALMONELLA TYPHI;

EID: 84864019616     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.007     Document Type: Article

References (54)

1. Cleland J.L. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol 1999, 17:25-29.
2. Jiang W.L., Gupta R.K., Deshpande M.C., Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005, 57:391-410.
3. O'Hagan D.T., Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 2004, 21:1519-1530.
4. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003, 2:727-735.
5. Babensee J.E. Interaction of dendritic cells with biomaterials. Semin Immunol 2008, 20:101-108.
6. Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007, 28:5344-5357.
7. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010, 9:1095-1107.
8. Yue H., Wei W., Yue Z., Lv P., Wang L., Ma G., et al. Particle size affects the cellular response in macrophages. Eur J Pharm Sci 2010, 41:650-657.
9. Cruz L.J., Tacken P.J., Fokkink R., Joosten B., Stuart M.C., Albericio F., et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010, 144:118-126.
10. Yoo J.-W., Irvine D.J., Discher D.E., Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011, 10:521-535.
11. Martinez-Veracoechea F.J., Frenkel D. Designing super selectivity in multivalent nano-particle binding. Pro Natl Acad Sci USA 2011, 108:10963-10968.
12. Papp I., Sieben C., Sisson A.L., Kostka J., Boettcher C., Ludwig K., et al. Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes. ChemBioChem 2011, 12:887-895.
13. Venter P.A., Dirksen A., Thomas D., Manchester M., Dawson P.E., Schneemann A. Multivalent display of proteins on viral nanoparticles using molecular recognition and chemical ligation strategies. Biomacromolecules 2011, 12:2293-2301.
14. Bondioli L., Costantino L., Ballestrazzi A., Lucchesi D., Boraschi D., Pellati F., et al. PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials 2010, 31:3395-3403.
15. Kanchan V., Katare Y.K., Panda A.K. Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics. Biomaterials 2009, 30:4763-4776.
16. Gupta R.K., Goswami D.G., Singh R.R., Surolia A., Panda A.K. Soybean agglutinin coated PLA particles entrapping candidate vaccines induces enhanced primary and sustained secondary antibody response from single point immunization. Eur J Pharm Sci 2012, 45:282-295.
17. Steenblock E.R., Fadel T., Labowsky M., Pober J.S., Fahmy T.M. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. J Biol Chem 2011, 286:34883-34892.
18. Zhou J., Patel T.R., Fu M., Bertram J.P., Saltzman W.M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012, 33:583-591.
19. Szewczyk B., Taylor A. Immunochemical properties of Vi antigen from Salmonella typhi-Ty2: presence of 2 antigenic determinants. Infect Immun 1980, 29:539-544.
20. Szewczyk B., Taylor A. Diversity of Vi-related antigens in the microcapsule of Salmonella typhi. Infect Immun 1980, 30:661-667.
21. Lebacq E. Comparative tolerability and immunogenicity of Typherix (TM) or Typhim Vi (TM) in healthy adults - 0, 12-month and 0, 24-month administration. BioDrugs 2001, 15:5-12.
22. Tacket C.O., Ferreccio C., Robbins J.B., Tsai C.M., Schulz D., Cadoz M., et al. Safety and immunogenicity of 2 Salmonella typhi Vi-capsular polysaccharide vaccines. J Infect Dis 1986, 154:342-345.
23. Tacket C.O., Levine M.M., Robbins J.B. Persistence of antibody-titers 3 years after vaccination with Vi polysaccharide vaccine against typhoid-fever. Vaccine 1988, 6:307-308.
24. Keitel W.A., Bond N.L., Zahradnik J.M., Cramton T.A., Robbins J.B. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994, 12:195-199.
25. Mond J.J., Vos Q., Lees A., Snapper C.M. T-cell independent antigens. Curr Opin Immunol 1995, 7:349-354.
26. Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations?. Nat Rev Drug Discov 2010, 9:308-324.
27. Lindberg A.A. Glycoprotein conjugate vaccines. Vaccine 1999, 17:S28-S36.
28. Poolman J., Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011, 10:307-322.
29. Pozsgay V. Synthesis of oligosaccharide-based glycoconjugate vaccines. Glycobiology 2001, 11:933-934.
30. Farkas P., Bystricky S. Chemical conjugation of biomacromolecules: a mini-review. Chemical Papers 2010, 64:683-695.
31. Guo Z., Wang Q. Recent development in carbohydrate-based cancer vaccines. Curr Opin Chem Biol 2009, 13:608-617.
32. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 1949, 180:249-261.
33. Yoshida M., Mata J., Babensee J.E. Effect of poly(lactic-co-glycolic acid) contact on maturation of murine bone marrow-derived dendritic cells. J Biomed Mater Res A 2007, 80A:7-12.
34. Katare Y.K., Panda A.K. Influences of excipients on in vitro release and in vivo performance of tetanus toxoid loaded polymer particles. Eur J Pharm Sci 2006, 28:179-188.
35. Katare Y.K., Muthukumaran T., Panda A.K. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005, 301:149-160.
36. Dagan R., Poolman J., Siegrist C.-A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28:5513-5523.
37. Poellabauer E.M., Petermann R., Ehrlich H.J. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 2009, 27:1674-1679.
38. Jegerlehner A., Wiesel M., Dietmeier K., Zabel F., Gatto D., Saudan P., et al. Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 2010, 28:5503-5512.
39. Peeters C., Tenbergenmeekes A.M., Poolman J.T., Beurret M., Zegers B.J.M., Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 1991, 59:3504-3510.
40. Guttormsen H.K., Sharpe A.H., Chandraker A.K., Brigtsen A.K., Sayegh M.H., Kasper D.L. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun 1999, 67:6375-6384.
41. Lai Z., Schreiber J.R. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine 2009, 27:3137-3144.
42. Colino J., Chattopadhyay G., Sen G., Chen Q., Lees A., Canaday D.H., et al. Parameters underlying distinct T cell-dependent polysaccharide-specific IgG responses to an intact gram-positive bacterium versus a soluble conjugate vaccine. J Immunol 2009, 183:1551-1559.
43. Looney R.J., Steigbigel R.T. Role of the Vi-antigen of Salmonella typhi in resistance to host defense in vitro. J Lab Clin Med 1986, 108:506-516.
44. Small J.M., Mitchell T.G. Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype-A. Infect Immun 1989, 57:3751-3756.
45. Garg R., Qadri A. Hemoglobin transforms anti-inflammatory Salmonella typhi virulence polysaccharide into a TLR-2 agonist. J Immunol 2010, 184:5980-5987.
46. Dhingra R.K., Williams R.C.J., Reed W.P. Effects of pneumococcal mucopeptide and capsular polysaccharides on phagocytosis. Infect Immun 1977, 15:169-174.
47. Garcia De Vinuesa C., Gulbranson-Judge A., Khan M., O'Leary P., Cascalho M., Wabl M., et al. Dendritic cells associated with plasmablast survival. Eur J Immunol 1999, 29:3712-3721.
48. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23:975-1028.
49. Cordero-Yap L., Rivera R.G., Dispo A.P., Mallabo J. Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2-5 years. BioDrugs 2001, 15:27. (Reprinted from Journal of Pediatrics 1999;48:85-88).
50. Szu S.C., Li X.R., Schneerson R., Vickers J.H., Bryla D., Robbins J.B. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera-toxin or its B-subunit as a carrier bound to high-molecular-weight or lower-molecular-weight Vi. Infect Immun 1989, 57:3823-3827.
51. de Veer M., Kemp J., Chatelier J., Elhay M.J., Meeusen E.N.T. The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant. Vaccine 2010, 28:6597-6602.
52. Kemp J.M., Kajihara M., Nagahara S., Sano A., Brandon M., Lofthouse S. Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses. Vaccine 2002, 20:1089-1098.
53. Cui C., Carbis R., An S.J., Jang H., Czerkinsky C., Szu S.C., et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010, 17:73-79.
54. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.